glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

Retatrutide Brand Name: What Will It Be Called?

Part of Retatrutide — All Topics.

Retatrutide Brand Name: What Will It Be Called?

Lilly has not announced a commercial brand name in its latest retatrutide updates. The medicine is still identified as retatrutide, its nonproprietary name, or LY3437943, its development code. “GLP-3” is an informal nickname, not a brand.
Lilly plans to submit a Biologics License Application (BLA) in Q1 2027. It has not confirmed an FDA approval date or a brand-name announcement date.

When Will the Brand Name Be Announced?

There is no confirmed announcement date. Proprietary-name review can begin before an application is submitted; it is not a process that must wait until approval. FDA checks proposed names for confusion and misleading claims.

A trademark filing or name circulating online is not, by itself, confirmation that Lilly will market retatrutide under that name. Look for a Lilly announcement or an eventual FDA-approved product label.

How Drug Brand Names Are Created

A pharmaceutical drug has three layers of naming:

Generic Name (retatrutide)

A nonproprietary name identifies the drug substance independently of a manufacturer's brand. WHO's naming system uses stems to indicate pharmacologic relationships. Its February 2026 pre-stem list includes -trutide for triple-agonist peptides acting at GLP-1, glucagon and GIP receptors. That supports the family meaning without inventing a separate origin for each syllable.

Brand Name (TBD)

Chosen by the pharmaceutical company, typically with help from specialized naming agencies. Must pass the FDA's Division of Medication Error Prevention and Analysis review, which evaluates whether the name could be confused with existing drugs in handwritten or spoken form. Trademark clearance is separate from FDA name review. A name passing one process does not establish approval through the other.

Development Code (LY3437943)

Internal identifier used during research. "LY" is Eli Lilly's standard prefix.

Lilly's Naming Pattern

Eli Lilly has established a precedent of using different brand names for different indications of the same molecule:

Swipe sideways to see every column.

Generic NameDiabetes BrandObesity BrandOther
TirzepatideMounjaroZepbound—
DulaglutideTrulicity——
RetatrutideTBDTBDNot announced

Tirzepatide shows that a single molecule can have different brands for different indications. It does not establish that Lilly will use the same approach for retatrutide.

What the Existing Names Tell Us

Existing product names tell us little about retatrutide's eventual name. FDA reviews how a proposed name looks and sounds, and whether it could imply unsupported benefits. Guesses based on the sound of Mounjaro or Zepbound are not evidence of Lilly's naming plan.

The -tide Suffix Explained

WHO lists -tide for peptides and glycopeptides. Its -trutide pre-stem describes antihyperglycaemic triple-agonist peptides acting at GLP-1, glucagon and GIP receptors.

This helps explain the nonproprietary name. It does not tell readers what brand Lilly will choose, whether the medicine is approved, or whether an online product contains authentic retatrutide.

Drug vs Biologic Classification

Lilly's current stated submission pathway is a Biologics License Application, planned for Q1 2027. Older reports discussing a possible NDA or litigation over classification should not be used as the current filing plan.

The application type is separate from the eventual commercial brand. It also does not make retatrutide available from a compounding pharmacy: FDA says retatrutide cannot be used in compounding under federal law.

Frequently Asked Questions

What is the brand name for retatrutide?

There is no brand name yet. Eli Lilly has not announced one. The drug is currently identified only as "retatrutide" (generic name) or LY3437943 (development code).

When will the brand name be announced?

No date has been announced. Lilly plans a BLA submission in Q1 2027, but has not tied a brand announcement to that milestone.

Will retatrutide have multiple brand names?

That is unknown. Mounjaro and Zepbound show that Lilly has used separate names for tirzepatide, but no equivalent retatrutide naming plan has been announced.

Is "GLP-3" a brand name?

No. "GLP-3" is an informal nickname used by patients and media to describe retatrutide as the next generation after GLP-1 drugs. It is not an official pharmaceutical name. See GLP-1 vs GLP-2 vs GLP-3 for the full explanation.

Sources

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all retatrutide topics →